Which substance inhibits intestinal motility?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Epinephrine Inhibits Intestinal Motility

Among the listed options, epinephrine (c) is the substance that inhibits intestinal motility. 1

Mechanism of Action of Each Substance

  • Epinephrine: Acts as a potent inhibitor of intestinal peristalsis by uncoupling the control activity to response activity through suppression of prepotentials in intestinal smooth muscle cells 2. It is approximately 500 times more potent at inhibiting intestinal motility compared to other catecholamines like dobutamine and dopexamine 1.

  • Gastrin: Not an inhibitor of intestinal motility. Gastrin primarily stimulates gastric acid secretion and has minimal effects on intestinal motility 3.

  • Cholecystokinin (CCK): Stimulates rather than inhibits intestinal motility. It primarily functions to stimulate gallbladder contraction and pancreatic enzyme secretion 3.

  • Motilin: Acts as a prokinetic agent that stimulates intestinal motility. Motilin receptor agonists like erythromycin are used to enhance gut motility in patients with gastrointestinal motility disorders 4.

  • Serotonin (5-HT): Generally promotes intestinal motility rather than inhibiting it. 5-HT4 receptor agonists like prucalopride are used as prokinetic agents to stimulate colonic peristalsis and enhance bowel motility 4.

Evidence Supporting Epinephrine's Inhibitory Effect

  • In comparative studies, epinephrine demonstrates the strongest inhibitory effect on intestinal peristalsis among catecholamines, with the rank order of inhibitory potency being: epinephrine > norepinephrine > dopamine > dobutamine ≈ dopexamine 1.

  • Electrophysiological studies show that epinephrine initially abolishes the response activity and prepotentials in intestinal smooth muscle cells, leading to inhibition of contractions 2.

  • The inhibitory effect of epinephrine on intestinal motility is mediated through alpha-2 adrenergic receptors, as demonstrated by studies showing that selective alpha-2 agonists delay small intestinal transit 5.

Clinical Implications

  • The inhibitory effect of epinephrine on intestinal motility explains why patients receiving epinephrine for shock or other indications may experience decreased gut motility 1.

  • Alpha-2 antagonists like atipamezole can reverse the inhibitory effects of alpha-2 agonists on intestinal motility, suggesting potential therapeutic applications for postoperative ileus 5.

  • Understanding the inhibitory effect of epinephrine on intestinal motility is important when managing critically ill patients who require catecholamine support, as this may contribute to ileus and feeding intolerance 1.

Comparison with Other Motility Modulators

  • Opioids also inhibit intestinal motility and are commonly used as antidiarrheal agents, with loperamide being the drug of choice due to its low risk of side effects 6.

  • Enkephalins and enkephalinase inhibitors have potent antisecretory properties in the intestine but their effects on motility are less pronounced compared to epinephrine 7.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Gut Motility Disorders

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

[Motility inhibitors and secretion inhibitors].

Schweizerische medizinische Wochenschrift. Supplementum, 1984

Research

Enkephalins and enkephalinase inhibitors in intestinal fluid and electrolyte transport.

European journal of gastroenterology & hepatology, 1997

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.